Clinical events and healthcare resource utilization associated with neutropenia and leukopenia among adult kidney transplant recipients receiving valganciclovir

Table 2 Adjusted clinical event rates for recurring events, by year after kidney transplantation

Number of events per person-year	Year 1 of follow-up with leukopenia/neutropenia, n = 11524 (A)		Year 1 of follow-up without leukopenia/neutropenia, n = 3874 (B)		Relative risk A/B	Year 2-5 of follow-up with leukopenia/neutropenia, n = 55831 (A)		Year 2-5 of follow-up without leukopenia/neutropenia, n = 90351 (B)		Relative risk A/B
	Event rate (%)	SE (%)	Event rate (%)	SE (%)		Event rate (%)	SE (%)	Event rate (%)	SE (%)
CMV DNAemia1	3	0.037	1.8	0.083	1.67	1.25	0.061	0.69	0.084	1.81
CMV disease	0.09	0.001	0.02	0.001	3.95	0.06	0.001	0.01	0	5.14
Opportunistic infections (excluding CMV)	2.19	0.009	1.57	0.012	1.4	1.15	0.007	0.76	0.005	1.52
G-CSF use	0.9	0.004	0.24	0.003	3.76	0.27	0.003	0.09	0.001	3.04
All-cause rehospitalization	2.24	0.013	1.52	0.013	1.47	0.95	0.011	0.52	0.005	1.84

¹Only patients with available cytomegalovirus DNAemia lab data were considered in the denominator for the rate of this event. In year 1 follow-up, this included 652 patients with leukopenia/neutropenia and 106 patients without leukopenia/neutropenia. In years 2-5 of follow-up, this included 258 patients with leukopenia/neutropenia and 148 patients without leukopenia/neutropenia.

CMV: Cytomegalovirus; G-CSF: Granulocyte colony stimulating factor.